Interviews

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

A decision from the American Board of Medical Specialties will be made about a new cardiovascular board by this upcoming February.

The connection between brain, mental, and cardiovascular health needs considerable more attention, argues Maureen Hood, PhD, RN, Uniformed Services University.

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

The upcoming Greater Philadelphia Business Coalition on Health (GPBCH) 2024 Mental Health Summit aims to address the growing recognition among employers of the critical role mental health plays in workplace productivity and overall well-being.

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

Oncology pharmacists play a vital role in managing complex outpatient therapies by assessing patient suitability, educating patients, and implementing protocols to ensure safe and effective treatment.

At our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Brita Roy, MD, MPH, MHS, spoke on improving cancer health outcomes through community-clinical partnerships.

In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk stratifying patients.

Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, explored the intricate management of alopecia areata, often in tandem with other autoimmune conditions while emphasizing the significance of innovative medications and diagnostic tools, such as dermoscopy, in enhancing patient outcomes.

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SERDs to improve patient outcomes.

As part of our coverage of the biennial AIDS conference from the International AIDS Society, we spoke with Madalitso Juwayeyi, program manager at FACT-Malawi, to learn more about her organization and how it strives to serve the sexual and reproductive health needs of adolescent girls and young women in her native Malawi.

Bonnie Qin, PhD, assistant professor at Rutgers Cancer institute, discusses factors that may influence adherence to dietary guidelines and improve survival for Black women with ovarian cancer.

The American Journal of Managed Care® and Vanderbilt University Medical Center partnered on a recent Institute for Value-Based Medicine® event, which had the theme, “Bringing the Future to the Present in Cancer Care.”

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, particularly regarding immune-related adverse events.

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

Bonnie Qin, PhD, of Rutgers Cancer Institute, emphasizes that moderate improvements in prediagnosis dietary quality can significantly enhance survival rates among Black women diagnosed with high-grade serous ovarian cancer.

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, including the latest diagnosis and treatment protocol advancements, at Advances in Pulmonary Medicine 2024.

Sanjula Jain, PhD, chief research officer at Trilliant Health, discusses the rapid adoption of glucagon-like peptide 1 inhibitors for diabetes and preventive care for obesity and late-onset diabetes.

The US could start catching up to Europe on biosimilars if the FDA removed the need for switching studies to be granted interchangeability.

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, highlighted recent breakthroughs in treating alopecia areata, focusing on the effectiveness of Janus kinase inhibitors and the ongoing challenges related to insurance coverage and patient access.

Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.

Carol R. Regueiro, MD, MSc, of Allegheny Health Network, highlights how the Physician Partners of Western PA practice support model has successfully engaged specialty practices to enhance patient connections and promote a population health perspective.

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions.